ID-1101

• CAT Number: I006993
• CAS Number: 55399-93-4
• Molecular Formula: C6H13NO3
• Molecular Weight: 147.174
• Purity: ≥95%
• Synonyms: ID-1101; 4-OH-Ile; 4OHIle; ID 1101; 4 OH Ile; ID1101;(2S,3R,4S)-4-Hydroxyisoleucine
• Target: Disease Research Fields
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: (2S,3R,4S)-2-amino-4-hydroxy-3-methylpentanoic acid
• InChI: InChI=1S/C6H13NO3/c1-3(4(2)8)5(7)6(9)10/h3-5,8H,7H2,1-2H3,(H,9,10)/t3-,4-,5-/m0/s1
• InChIKey: OSCCDBFHNMXNME-YUPRTTJUSA-N
• SMILES: CC(C(C)O)C(C(=O)O)N

ID-1101 (Cat. No: I006993), also known as (2S, 3R, 4S) -4-Hydroxyisoleucine, is an oral active ingredient isolated from fenugreek. It has the activities of promoting insulin secretion, anti-diabetes, and anti-diabetic nephropathy, and can be used to treat type II diabetes.

Reference

1:Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E463-71. Epub 2004 Apr 13. Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat.Broca C,Breil V,Cruciani-Guglielmacci C,Manteghetti M,Rouault C,Derouet M,Rizkalla S,Pau B,Petit P,Ribes G,Ktorza A,Gross R,Reach G,Taouis M, PMID: 15082420 DOI: 10.1152/ajpendo.00163.2003 Abstract: ID-1101 (4-hydroxyisoleucine), an amino acid extracted from fenugreek seeds, exhibits an interesting glucose-dependent insulin-stimulating activity. The present study was undertaken to investigate a possible extrapancreatic effect of ID-1101 on insulin signaling and action besides its previously described insulinotropic action. Insulin-sensitizing effects of ID-1101 were investigated in rat in vivo by three different approaches: 1) using euglycemic hyperinsulinemic clamps in two different rat models of insulin resistance, i.e., Zucker fa/fa rats and rats fed a sucrose-lipid diet; 2) measuring liver and muscle phosphatidylinositol (PI) 3-kinase activity after an acute injection of ID-1101 in normal and insulin-resistant diabetic rats; and 3) after chronic treatment in two rat models of insulin resistance. Euglycemic hyperinsulinemic clamp experiments revealed that ID-1101 can improve insulin resistance through an increase of peripheral glucose utilization rate in sucrose-lipid-fed rats and by decreasing hepatic glucose production in Zucker fa/fa rats. Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats. Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats. These findings clearly demonstrate that ID-1101 can reduce insulin resistance through activation of the early steps of insulin signaling in peripheral tissues and in liver. In summary, ID-1101, besides its insulinotropic effect, directly improves insulin sensitivity, making it a potentially very valuable therapeutic agent for diabetes treatment.